Virax BiolabsVRAX
About: Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Employees: 17
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
40% more funds holding
Funds holding: 5 [Q3] → 7 (+2) [Q4]
3.58% less ownership
Funds ownership: 5.03% [Q3] → 1.45% (-3.58%) [Q4]
67% less capital invested
Capital invested by funds: $424K [Q3] → $141K (-$282K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for VRAX.
Financial journalist opinion
Based on 3 articles about VRAX published over the past 30 days









